We are creating some awesome events for you. Kindly bear with us.

Sonobiopsy Revolutionising Brain Disease Diagnosis

Image credits: source.wustl.edu

Scientists from Washington University in St. Louis have created a sonobiopsy method to diagnose brain disease.  The Sonobiopsy method employs ultrasound and microbubbles to momentarily breach the barrier, enabling brain RNA, DNA, and proteins to enter the bloodstream for analysis. While this technique was initially tested on animals, a recent study demonstrates its safety and viability for human use. This innovation may pave the way for non-invasive brain disease and tumour diagnostics.

Eric Leuthardt, MD, co-senior author and co-inventor of the technology, stated that Magnetic Resonance Imaging (MRI) drastically transformed brain disease diagnosis in the 1980s and ’90s, offering structural and functional brain imaging capabilities.

Leuthardt, the Shi Hui Huang Professor of Neurosurgery and a professor of neuroscience at the School of Medicine in biomedical engineering and mechanical engineering at the McKelvey School of Engineering referred to sonobiopsy as the third revolution, emphasising its molecular aspect. This innovative technique allows blood sample collection reflecting gene expression and molecular characteristics at the brain lesion site, essentially performing a brain biopsy without the associated risks of surgery.

Eric Leuthardt and Hong Chen, PhD, Associate Professors of Biomedical Engineering at McKelvey Engineering and Neurosurgery at the School of Medicine, developed the groundbreaking technique, focusing on multidisciplinary research to create engineered solutions for neurological diseases.

The technique employs focused ultrasound to target a brain lesion at a millimetre scale. Subsequently, microbubbles are injected into the bloodstream, travelling to the designated area and bursting, creating minuscule, temporary openings in the blood-brain barrier. These openings naturally close within a few hours, causing no lasting harm. Within this time frame, brain lesion biomolecules can exit the bloodstream, facilitating their collection through a standard blood draw.

Hong Chen, another Senior Co-author and co-inventor of the technology described this innovation as initiating a new field for brain-related conditions. It offers the capability to noninvasively and nondestructively access all brain regions, enabling the retrieval of genetic information about tumours before surgical procedures.

This information aids neurosurgeons in determining the best approach to surgery, helping confirm the nature of suspicious findings on imaging. Furthermore, it paves the way for studying diseases that typically don’t undergo surgical biopsies, including neurodevelopmental, neurodegenerative, and psychiatric disorders.

Initially, the researchers utilised a commercially available ultrasound device combined with an MRI scanner, a setup limited by cost and MRI availability. To streamline the procedure, Hong Chen’s team designed a portable, handheld ultrasound probe that could be attached to a stereotactic pointer commonly used by neurosurgeons for pinpointing brain lesions. This device was seamlessly integrated into the clinical workflow, requiring no additional training for neurosurgeons.

Eric Leuthardt emphasised the user-friendliness of this device, stating that it was efficiently utilised during the study in the operating room but could also be employed in a clinic or at a patient’s bedside in a hospital. He noted that this approach was a significant step toward making advanced diagnostics more accessible, enabling the examination of patients’ brains without needing a high-tech, multimillion-dollar scanner.

In their research, the team conducted sonobiopsies on five individuals with brain tumours using this device. Subsequently, the tumours were removed surgically following the standard care protocol.

The analysis of blood samples collected before and after sonication revealed that the technique increased circulating tumour DNA, ranging from 1.6-fold to 5.6-fold, depending on the specific type of DNA examined.

Circulating tumour DNA holds crucial information about genetic alterations in a patient’s tumour, which guides treatment decisions regarding the tumour’s aggressiveness. Notably, the procedure showed no signs of causing damage to brain tissue, affirming its safety.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend